CN116196458A - Healing-promoting dressing for chronic wounds and preparation method thereof - Google Patents
Healing-promoting dressing for chronic wounds and preparation method thereof Download PDFInfo
- Publication number
- CN116196458A CN116196458A CN202310288558.3A CN202310288558A CN116196458A CN 116196458 A CN116196458 A CN 116196458A CN 202310288558 A CN202310288558 A CN 202310288558A CN 116196458 A CN116196458 A CN 116196458A
- Authority
- CN
- China
- Prior art keywords
- dressing
- healing
- uamc
- pva
- sod
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010052428 Wound Diseases 0.000 title claims abstract description 38
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 38
- 230000001684 chronic effect Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 18
- HSYSVXKJIVUNBR-UHFFFAOYSA-N 3-(benzylamino)-4-(cyclohexylamino)-N-(2-piperazin-1-ylethyl)benzenesulfonamide Chemical compound C(C1=CC=CC=C1)NC=1C=C(C=CC=1NC1CCCCC1)S(=O)(=O)NCCN1CCNCC1 HSYSVXKJIVUNBR-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000004433 Thermoplastic polyurethane Substances 0.000 claims abstract description 11
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 claims abstract description 11
- 230000029663 wound healing Effects 0.000 claims abstract description 11
- 238000001523 electrospinning Methods 0.000 claims abstract description 10
- 239000012528 membrane Substances 0.000 claims abstract description 10
- 239000002121 nanofiber Substances 0.000 claims abstract description 10
- 239000012792 core layer Substances 0.000 claims abstract description 9
- 230000035876 healing Effects 0.000 claims abstract description 8
- 230000008569 process Effects 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 48
- 238000009987 spinning Methods 0.000 claims description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 26
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 claims description 26
- 229920001610 polycaprolactone Polymers 0.000 claims description 19
- 239000004632 polycaprolactone Substances 0.000 claims description 19
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 238000006116 polymerization reaction Methods 0.000 claims description 14
- 239000004698 Polyethylene Substances 0.000 claims description 12
- 229920000573 polyethylene Polymers 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 10
- 238000006136 alcoholysis reaction Methods 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 239000010410 layer Substances 0.000 claims description 7
- 150000003904 phospholipids Chemical class 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 6
- ZLGYVWRJIZPQMM-HHHXNRCGSA-N 2-azaniumylethyl [(2r)-2,3-di(dodecanoyloxy)propyl] phosphate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCC ZLGYVWRJIZPQMM-HHHXNRCGSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- 239000002502 liposome Substances 0.000 abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 abstract description 4
- 239000001301 oxygen Substances 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 239000011258 core-shell material Substances 0.000 abstract description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 abstract 3
- 108010012715 Superoxide dismutase Proteins 0.000 abstract 3
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 2
- 229920002803 thermoplastic polyurethane Polymers 0.000 abstract 2
- 238000006555 catalytic reaction Methods 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000007789 gas Substances 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 34
- 229910052742 iron Inorganic materials 0.000 description 16
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 230000034994 death Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 229960003180 glutathione Drugs 0.000 description 6
- 229940118019 malondialdehyde Drugs 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 238000010041 electrostatic spinning Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000008113 selfheal Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/38—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0015—Electro-spinning characterised by the initial state of the material
- D01D5/003—Electro-spinning characterised by the initial state of the material the material being a polymer solution or dispersion
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
- D01D5/0061—Electro-spinning characterised by the electro-spinning apparatus
- D01D5/0069—Electro-spinning characterised by the electro-spinning apparatus characterised by the spinning section, e.g. capillary tube, protrusion or pin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mechanical Engineering (AREA)
- Textile Engineering (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of biomedical materials, and discloses a healing-promoting dressing for chronic wounds and a preparation method thereof. The preparation method comprises the following steps: and (3) preparing a superoxide dismutase (SOD) -UAMC-3203/phospholipid-3 beta- [ N- (N ', N' -dimethyl amine ethyl) amino formyl ] cholesterol (DC-Chol) -deferoxamine core shell polyvinyl alcohol (PVA) -polyvinylpyrrolidone (PVP)/Thermoplastic Polyurethane (TPU) nanofiber membrane by coaxial electrospinning, namely the chronic wound healing dressing. The dressing utilizes free radicals at the wound to generate oxygen through the catalysis of the SOD of the core layer, and the UAMC-3203 is packed into self-assembled liposome in the gas overflowing process, so that the utilization rate of the UAMC-3203 can be effectively improved, and the healing of chronic wounds is accelerated.
Description
Technical Field
The invention belongs to the field of biomedical materials, and particularly relates to a healing-promoting dressing for chronic wounds and a preparation method thereof.
Background
Chronic refractory wounds refer to wounds that fail to self-heal normally to an anatomically original state or have no tendency to heal over a period of more than 1 month. Such wounds or wounds cannot shrink by themselves by 10% -15%/week or 50%/month. The incidence rate of chronic wounds is 1% -2%, the chronic wounds have the characteristics of complex pathogenesis, long disease course, high cost and the like, and the incidence rate is obviously increased along with the acceleration of aging of population. The primary disease of patients is cured, the life quality is seriously affected by the long disease course of chronic difficult-to-heal wounds, and families also bear heavy nursing and economic burden. If infection spread occurs in a few chronic refractory wounds, complications such as sepsis and the like can be caused, and ulcer canceration can occur in severe cases. Recent studies have found that lipid peroxidation, i.e. iron death, caused by iron-dependent, ROS-increase is one of the molecular mechanisms of chronic wound healing.
Dressing is an effective method of treating chronic wounds, but many chronic wound dressings today employ natural biological tissue that needs to be obtained from a donor and processed into a material, which is often a very complex process and requires high costs.
Disclosure of Invention
In view of the above, the present invention aims to provide a healing promoting dressing for chronic wounds, which is capable of self-assembling and releasing UAMC-3203 liposome, and an effect of promoting wound healing, and a preparation method thereof.
In order to solve the technical problems, the invention provides a healing promoting dressing for chronic wounds and a preparation method thereof, and the healing promoting dressing comprises the following steps:
s1, adding phospholipid, DC-Chol, deferoxamine-polyethylene glycol-polycaprolactone and TPU into N, N-dimethylformamide, and fully and uniformly mixing to obtain a shell spinning solution;
s2, adding UAMC-3203, nano manganese dioxide and SOD into the PVA-PVP solution, and fully and uniformly mixing to obtain a core spinning solution;
s3, spinning the shell layer spinning solution prepared in the step S1 and the core layer spinning solution prepared in the step S2 into a nanofiber membrane by utilizing coaxial electrospinning, and drying in vacuum to obtain the chronic wound healing dressing.
Preferably, in step S1, the phospholipid, DC-Chol, deferoxamine-polyethylene glycol-polycaprolactone, TPU and N, N-dimethylformamide are used in a proportion of (100-120) mg (40-100) mg (14-18) mg (2-4) g (20-25) mL.
Preferably, in step S1, the phospholipid is one of 1, 2-dimyristoyl-sn-glycero-3-phosphorylcholine or 1, 2-dilauroyl-sn-glycero-3-phosphoethanolamine.
Preferably, in step S1, the degree of polymerization of polyethylene glycol in the deferoxamine-polyethylene glycol-polycaprolactone is 20-40, and the degree of polymerization of polycaprolactone is 15-30.
Preferably, in step S1, the TPU is one of Texin RxT70A, NRUX1368 or Lubrizol S395 AH-27N.
Preferably, in the step S2, the UAMC-3203, the nano manganese dioxide and the SOD are added into the PVA-PVP solution in the dosage proportion of (100-125) mg (40-50) mg (200-450) mg (20-45) mL.
Preferably, in the step S2, the particle size of the nano manganese dioxide is 10-20nm, and the enzyme activity of SOD is 10000-40000U/g.
Preferably, in step S2, the PVA has a weight average molecular weight of 90000-120000, an alcoholysis degree of 87-89%, a concentration of 120-150g/L, a weight average molecular weight of 45000-58000, and a concentration of 2-7g/L.
Preferably, in the step S3, the coaxial electrostatic spinning condition is that the voltage is 30-36kV, the receiving distance is 10-15cm, the injection rate of the core layer is 0.5-0.7mL/h, and the injection rate of the shell layer is 0.8-1.2mL/h.
The invention also provides the healing-promoting dressing prepared by the preparation method.
Compared with the prior art, the invention has the following beneficial effects:
1) And wrapping SOD on a core layer of the core-shell nanofiber, catalyzing free radicals in wound exudates to release oxygen, and packaging through an outer lipid membrane to obtain the free UAMC-3203 liposome. The DC-Chol is adopted, so that the surface of the self-assembled liposome is positively charged, the adsorption of cell membranes is facilitated, iron and free radicals in wound exudates are not contacted with UAMC-3203, and the iron-free radicals directly enter cells, so that the function of inhibiting iron death is exerted.
2) The deferoxamine-polyethylene glycol-polycaprolactone on the outer layer of the fiber can chelate iron, prevent the iron from entering the core layer to generate Fenton reaction, and avoid the failure of UAMC-3203.
3) The hydrophobic structure of the TPU also prevents rapid erosion of the fibrous core, making release and action more durable.
Drawings
FIG. 1 shows the results of an 8-OhdG assay in wound tissue;
FIG. 2 is a graph showing the measurement of iron cell death markers relative to GSH levels;
fig. 3 is a graph showing the results of a cellular iron death marker versus MDA level assay.
Detailed Description
For a further understanding of the present invention, preferred embodiments of the invention are described below in conjunction with the examples, but it should be understood that these descriptions are merely intended to illustrate further features and advantages of the invention, and are not limiting of the claims of the invention.
Example 1
1. 110mg of 1, 2-dimyristoyl-sn-glycero-3-phosphorylcholine, 60mg of DC-Chol and 17mg of deferoxamine-polyethylene glycol-polycaprolactone, wherein the polymerization degree of polyethylene glycol is 22, the polymerization degree of polycaprolactone is 18 and 3g Texin RxT70ATPU are added into 22mLN, N-dimethylformamide, and the mixture is fully and uniformly mixed to obtain a shell spinning solution;
2. 120mg of UAMC-3203, 48mg of manganese dioxide powder with the particle size of 15nm and 400mg of SOD with the enzyme activity of 30000U/g are added into 25mL of PVA-PVP solution, and the mixture is fully and uniformly mixed to obtain a core spinning solution, wherein the weight average molecular weight of PVA in the PVA-PVP solution is 100000, the alcoholysis degree is 88%, the concentration is 130g/L, the weight average molecular weight of PVP is 50000, and the concentration is 3.8g/L;
3. and spinning the shell spinning solution and the core spinning solution into a nanofiber membrane by utilizing coaxial electrospinning voltage of 35kV and a receiving distance of 12cm, wherein the core injection rate is 0.6mL/h and the shell injection rate is 0.95mL/h, and obtaining the chronic wound healing-promoting dressing after vacuum drying.
Example 2
1. 100mg of 1, 2-dilauroyl-sn-glycero-3-phosphoethanolamine, 40mg of DC-Chol and 18mg of deferoxamine-polyethylene glycol-polycaprolactone, wherein the polymerization degree of the polyethylene glycol is 20, the polymerization degree of the polycaprolactone is 30 and 2g of NRUX1368 TPU are added into 20mL of N, N-dimethylformamide, and the mixture is fully and uniformly mixed to obtain a shell spinning solution;
2. adding 100mg of UAMC-3203, 50mg of manganese dioxide powder with the particle size of 20nm and 200mg of SOD with the enzyme activity of 40000U/g into 20mL of PVA-PVP solution, and fully and uniformly mixing to obtain a core spinning solution, wherein the weight average molecular weight of PVA in the PVA-PVP solution is 90000, the alcoholysis degree is 89%, the concentration is 120g/L, the weight average molecular weight of PVP is 45000, and the concentration is 2g/L;
3. and spinning the shell spinning solution and the core spinning solution into a nanofiber membrane by utilizing coaxial electrospinning voltage of 36kV, receiving distance of 15cm, core injection rate of 0.5mL/h and shell injection rate of 1.2mL/h, and vacuum drying to obtain the chronic wound healing-promoting dressing.
Example 3
1. 120mg of phospholipid 1, 2-dimyristoyl-sn-glycero-3-phosphorylcholine, 100mg of DC-Chol and 14mg of deferoxamine-polyethylene glycol-polycaprolactone, wherein the polymerization degree of the polyethylene glycol is 40, the polymerization degree of the polycaprolactone is 15 and 4g Lubrizol S395AH-27N TPU is added into 25mL of N, N-dimethylformamide, and the mixture is fully and uniformly mixed to obtain a shell spinning solution;
2. adding 125mg of UAMC-3203, 40mg of manganese dioxide powder with the particle size of 10nm and 450mg of SOD with the enzyme activity of 10000U/g into 45mL of PVA-PVP solution, and fully and uniformly mixing to obtain a core spinning solution, wherein the weight average molecular weight of PVA in the PVA-PVP solution is 120000, the alcoholysis degree is 87%, the concentration is 150g/L, the weight average molecular weight of PVP is 58000, and the concentration is 7g/L;
3. and spinning the shell spinning solution and the core spinning solution into a nanofiber membrane by using a coaxial electrospinning voltage of 30kV and a receiving distance of 10cm, wherein the core injection rate is 0.7mL/h and the shell injection rate is 0.8mL/h, and obtaining the chronic wound healing-promoting dressing after vacuum drying.
Comparative example 1 (without deferoxamine)
A dressing and a preparation method thereof, comprising the following steps:
1. 110mg of 1, 2-dimyristoyl-sn-glycero-3-phosphorylcholine, 60mg of DC-Chol and 3g Texin RxT70ATPU are added into 22mL of N, N-dimethylformamide, and the mixture is fully and uniformly mixed to obtain a shell spinning solution;
2. 120mg of UAMC-3203, 48mg of manganese dioxide powder with the particle size of 15nm and 400mg of SOD with the enzyme activity of 30000U/g are added into 25mL of PVA-PVP solution, and the mixture is fully and uniformly mixed to obtain a core spinning solution, wherein the weight average molecular weight of PVA in the PVA-PVP solution is 100000, the alcoholysis degree is 88%, the concentration is 130g/L, the weight average molecular weight of PVP is 50000, and the concentration is 3.8g/L;
3. and spinning the shell spinning solution and the core spinning solution into a nanofiber membrane by using a coaxial electrospinning voltage of 35kV and a receiving distance of 12cm, wherein the injection rate of the core layer is 0.6mL/h, the injection rate of the shell layer is 0.95mL/h, and vacuum drying is carried out to obtain the dressing.
Comparative example 2 (SOD free)
A dressing and a preparation method thereof, comprising the following steps:
1. 110mg of 1, 2-dimyristoyl-sn-glycero-3-phosphorylcholine, 60mg of DC-Chol and 17mg of deferoxamine-polyethylene glycol-polycaprolactone, wherein the polymerization degree of polyethylene glycol is 22, the polymerization degree of polycaprolactone is 18 and 3g Texin RxT70ATPU are added into 22mLN, N-dimethylformamide, and the mixture is fully and uniformly mixed to obtain a shell spinning solution;
2. adding 120mg of UAMC-3203 and 48mg of manganese dioxide powder with the particle size of 15nm into 25mL of PVA-PVP solution, and fully and uniformly mixing to obtain core spinning solution, wherein in the PVA-PVP solution, the weight average molecular weight of PVA is 100000, the alcoholysis degree is 88%, the concentration is 130g/L, the weight average molecular weight of PVP is 50000, and the concentration is 3.8g/L;
3. and spinning the shell spinning solution and the core spinning solution into a nanofiber membrane by using a coaxial electrospinning voltage of 35kV and a receiving distance of 12cm, wherein the injection rate of the core layer is 0.6mL/h, the injection rate of the shell layer is 0.95mL/h, and vacuum drying is carried out to obtain the dressing.
Comparative example 3 (lipid free)
A dressing and a preparation method thereof, comprising the following steps:
1. 17mg of deferoxamine-polyethylene glycol-polycaprolactone, wherein the polymerization degree of polyethylene glycol is 22, the polymerization degree of polycaprolactone is 18 and 3g Texin RxT70ATPU are added into 22mL of N, N-dimethylformamide, and the mixture is fully and uniformly mixed to obtain a shell spinning solution;
2. 120mg of UAMC-3203, 48mg of manganese dioxide powder with the particle size of 15nm and 400mg of SOD with the enzyme activity of 30000U/g are added into 25mL of PVA-PVP solution, and the mixture is fully and uniformly mixed to obtain a core spinning solution, wherein the weight average molecular weight of PVA in the PVA-PVP solution is 100000, the alcoholysis degree is 88%, the concentration is 130g/L, the weight average molecular weight of PVP is 50000, and the concentration is 3.8g/L;
3. and spinning the shell spinning solution and the core spinning solution into a nanofiber membrane by using a coaxial electrospinning voltage of 35kV and a receiving distance of 12cm, wherein the injection rate of the core layer is 0.6mL/h, the injection rate of the shell layer is 0.95mL/h, and vacuum drying is carried out to obtain the dressing.
Chronic wound healing experiment for rat
And constructing a chronic wound model of the diabetic rats by adopting 4-month-old Wistar male rats. The dressing of examples 1-3 and comparative examples 1-3 was used to treat wound surface, the dressing was changed every 2 days, and wound healing was recorded, and the results are shown in Table 1.
TABLE 1 wound healing Condition (5 per group)
From Table 1, it is clear that the chronic refractory wounds of the diabetic rats treated with the dressing of examples 1 to 3 were substantially completely healed within 6 days. Whereas the wound surface treated with the dressing of comparative examples 1 to 3 was difficult to heal. For the explanation of this, we determined the content of 8-OHdG in wound tissue.
Determination of 8-OHdG content in wound tissue
And constructing a chronic wound model of the diabetic rats by adopting 4-month-old Wistar male rats. The dressing of examples 1-3 and comparative examples 1-3 were used to treat the wound, the dressing was changed every 2 days, rats were sacrificed after 4 days, wound tissues were taken, and the content of 8-OHdG was measured, and the results are shown in FIG. 1.
As can be seen from fig. 1, the dressing of examples 1-3 treated wound tissue for 4d, the DNA within the nucleus was not significantly damaged by ROS, mainly because the SOD of the fiber core converted ROS to hydrogen peroxide, which was then catalyzed by manganese dioxide to generate oxygen, promoting wound healing and shortening healing time (table 1). The dressing of comparative example 1, however, did not sequester free iron, resulting in an inability to interrupt the Fenton reaction, and ROS remained at high levels, resulting in lipid peroxidation, DNA fragmentation, and increased 8-OHdG content. The dressing of comparative example 2 did not convert ROS to hydrogen peroxide without SOD, and excessive ROS accumulation resulted in lipid peroxidation, increased 8-OHdG content, iron death, and slow wound healing. The dressing of comparative example 3 did not have lipid-entrapped UAMC-3203, which easily reacted with free iron and ROS, lost activity, failed to exert the effect of inhibiting lipid peroxidation and iron death in cells, increased 8-OhdG content, and failed to heal wound effectively.
Cellular iron death marker assay
Adopting high-sugar DMEM culture medium as basic solution, adding 10% fetal bovine serum, and adding 1.0mmol/L H 2 O 2 And FeCl 2 The concentration of Fe (II) reaches 30.0 mu mol/L and the double antibody simulates the micro environment of the chronic wound surface. NIH3T3 cells were cultured at 1% oxygen concentration and incubated with the dressings of examples 1-3 and comparative examples 1-3 for 24h. Intracellular relative Glutathione (GSH) and Malondialdehyde (MDA) levels were measured, with normally cultured NIH3T3 cells as controls, and the results are shown in figures 2 and 3.
GSH and MDA are markers of iron death. From FIGS. 2 and 3, it can be seen that the NIH3T3 cells treated with the dressing of examples 1-3 reduced iron death from iron-dependent ROS increase, and intracellular GSH and MDA levels were near normal. Whereas the cells treated with the dressing of comparative examples 1-3 had intracellular GSH levels reduced below 50% while MDA increased approximately 1-fold, indicating that iron death had occurred in the cells, a key cause of difficult wound healing.
The invention provides a dressing for promoting healing of chronic wounds, a method for preparing the dressing, and a method for preparing the dressing, wherein the method and the method for realizing the technical scheme are a plurality of methods, the method is only a preferred embodiment of the invention, and it should be pointed out that a plurality of improvements and modifications can be made by one of ordinary skill in the art without departing from the principle of the invention, and the improvements and modifications are also considered as the protection scope of the invention. The components not explicitly described in this embodiment can be implemented by using the prior art.
Claims (10)
1. A method of preparing a healing promoting dressing for a chronic wound, comprising the steps of:
s1, adding phospholipid, DC-Chol, deferoxamine-polyethylene glycol-polycaprolactone and TPU into N, N-dimethylformamide, and fully and uniformly mixing to obtain a shell spinning solution;
s2, adding UAMC-3203, nano manganese dioxide and SOD into the PVA-PVP solution, and fully and uniformly mixing to obtain a core spinning solution;
s3, spinning the shell layer spinning solution and the core layer spinning solution into a nanofiber membrane by utilizing coaxial electrospinning, and drying in vacuum to obtain the chronic wound healing dressing.
2. The method according to claim 1, wherein the ratio of the amounts of the phospholipid, DC-Chol, deferoxamine-polyethylene glycol-polycaprolactone, TPU and N, N-dimethylformamide in step S1 is (100-120) mg (40-100) mg (14-18) mg (2-4) g (20-25) mL.
3. The method according to claim 1, wherein in step S1, the phospholipid is 1, 2-dimyristoyl-sn-glycero-3-phosphorylcholine or 1, 2-dilauroyl-sn-glycero-3-phosphoethanolamine.
4. The method according to claim 1, wherein in step S1, the degree of polymerization of polyethylene glycol in the deferoxamine-polyethylene glycol-polycaprolactone is 20 to 40 and the degree of polymerization of polycaprolactone is 15 to 30.
5. The process according to claim 1, wherein in step S1, the TPU is one of TexinRxT70A, NRUX1368 and LubrizolS395 AH-27N.
6. The method of claim 1, wherein in step S2, the UAMC-3203, nano manganese dioxide and SOD are added to the PVA-PVP solution in an amount of (100-125) mg (40-50) mg (200-450) mg (20-45) mL.
7. The method according to claim 1, wherein in step S2, the nano manganese dioxide has a particle size of 10-20nm and an enzyme activity of 10000-40000U/g of sod.
8. The method according to claim 1, wherein in step S2, the PVA has a weight average molecular weight of 90000-120000, an alcoholysis degree of 87-89%, a concentration of 120-150g/L, a weight average molecular weight of 45000-58000, and a concentration of 2-7g/L.
9. The method according to claim 1, wherein in the step S3, the coaxial electrospinning condition is that the voltage is 30-36kV, the receiving distance is 10-15cm, the core injection rate is 0.5-0.7mL/h, and the shell injection rate is 0.8-1.2mL/h.
10. The healing promoting dressing prepared by the preparation method according to any one of claims 1 to 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310288558.3A CN116196458B (en) | 2023-03-23 | 2023-03-23 | Healing-promoting dressing for chronic wounds and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310288558.3A CN116196458B (en) | 2023-03-23 | 2023-03-23 | Healing-promoting dressing for chronic wounds and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116196458A true CN116196458A (en) | 2023-06-02 |
| CN116196458B CN116196458B (en) | 2024-08-20 |
Family
ID=86509534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310288558.3A Active CN116196458B (en) | 2023-03-23 | 2023-03-23 | Healing-promoting dressing for chronic wounds and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116196458B (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5549910A (en) * | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| CA2666158A1 (en) * | 2008-05-22 | 2009-11-22 | Honeywell International Inc. | Functional nano-layered hemostatic material/device |
| CA2764060A1 (en) * | 2009-06-25 | 2010-12-29 | Darlene Mccord | Topical compositions and methods for wound care |
| CN101947312A (en) * | 2010-08-26 | 2011-01-19 | 董萍 | Modified polyethylene glycol superoxide dismutase (mPEG-SOD) nanoemulsion capable of being directly externally used for skin and preparation method thereof |
| US20130266545A1 (en) * | 2009-06-25 | 2013-10-10 | Darlene E. McCord | Methods for improved wound closure employing olivamine and human umbilical vein endothelial cells |
| CN103813766A (en) * | 2011-09-14 | 2014-05-21 | 3M创新有限公司 | Positive pressure medical dressings with valve and kits containing same |
| WO2015172153A1 (en) * | 2014-05-09 | 2015-11-12 | Yale University | Topical formulation of hyperbranched polyglycerol-coated particles thereof |
| CN111514150A (en) * | 2020-05-22 | 2020-08-11 | 清华大学 | Application of TPPO in inhibiting FPP-induced cell death and corresponding reperfusion injury |
| CN112169014A (en) * | 2020-09-27 | 2021-01-05 | 浙江丽能生物医药科技有限公司 | Material for promoting rapid repair of skin surface wound by SOD (superoxide dismutase) and preparation method thereof |
| CN113876995A (en) * | 2021-09-26 | 2022-01-04 | 上海交通大学医学院附属第九人民医院 | Nanofiber membrane for skin wound and preparation method thereof |
-
2023
- 2023-03-23 CN CN202310288558.3A patent/CN116196458B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5549910A (en) * | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| CA2666158A1 (en) * | 2008-05-22 | 2009-11-22 | Honeywell International Inc. | Functional nano-layered hemostatic material/device |
| CA2764060A1 (en) * | 2009-06-25 | 2010-12-29 | Darlene Mccord | Topical compositions and methods for wound care |
| US20130266545A1 (en) * | 2009-06-25 | 2013-10-10 | Darlene E. McCord | Methods for improved wound closure employing olivamine and human umbilical vein endothelial cells |
| CN101947312A (en) * | 2010-08-26 | 2011-01-19 | 董萍 | Modified polyethylene glycol superoxide dismutase (mPEG-SOD) nanoemulsion capable of being directly externally used for skin and preparation method thereof |
| CN103813766A (en) * | 2011-09-14 | 2014-05-21 | 3M创新有限公司 | Positive pressure medical dressings with valve and kits containing same |
| WO2015172153A1 (en) * | 2014-05-09 | 2015-11-12 | Yale University | Topical formulation of hyperbranched polyglycerol-coated particles thereof |
| CN111514150A (en) * | 2020-05-22 | 2020-08-11 | 清华大学 | Application of TPPO in inhibiting FPP-induced cell death and corresponding reperfusion injury |
| CN112169014A (en) * | 2020-09-27 | 2021-01-05 | 浙江丽能生物医药科技有限公司 | Material for promoting rapid repair of skin surface wound by SOD (superoxide dismutase) and preparation method thereof |
| CN113876995A (en) * | 2021-09-26 | 2022-01-04 | 上海交通大学医学院附属第九人民医院 | Nanofiber membrane for skin wound and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| JIAPENG TANG ET AL: "Silver Nanoparticle-Anchored Human Hair Kerateine/PEO/PVA Nanofibers for Antibacterial Application and Cell Proliferation", MOLECULES, 8 May 2021 (2021-05-08), pages 1 - 15 * |
| PANELKAROLA VORAUER-UHL ET AL: "Topically applied liposome encapsulated superoxide dismutase reduces postburn wound size and edema formation", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 10 July 2001 (2001-07-10), pages 63 - 67 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116196458B (en) | 2024-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1951328B1 (en) | Sustained release film formulation for healing wound comprising epidermal growth factor | |
| RU2212884C2 (en) | Preparations used for administration of anti- -inflammatory and especially antiseptic agents and/or agent promoting to wound healing into lower respiratory way | |
| WO2022088566A1 (en) | Nanofiber facial mask containing liposome and preparation method therefor | |
| Pinto et al. | Emerging nitric oxide and hydrogen sulfide releasing carriers for skin wound healing therapy | |
| Lai et al. | A stimuli-responsive nanoparticulate system using poly (ethylenimine)-graft-polysorbate for controlled protein release | |
| CN112315660B (en) | Biodegradable nanofiber medical bandage and preparation method thereof | |
| CN116196458B (en) | Healing-promoting dressing for chronic wounds and preparation method thereof | |
| CN115475272B (en) | Preparation method of nanofiber membrane with antibacterial anti-blocking function | |
| CN114524950A (en) | Magnetic targeting hydrophobic drug carrier hydrogel and preparation method and application thereof | |
| CN112807475A (en) | High-air-permeability degradable drug-loaded skin wound dressing and preparation method thereof | |
| CN116139322B (en) | Wound dressing and preparation method thereof | |
| CN112807443B (en) | Multiple synergistic antibacterial nano prodrug | |
| WO2024045224A1 (en) | Multi-stage pore hydrogel medicament sustained-release system based on natural polyphenol and preparation method therefor | |
| KR20100017345A (en) | Biocidic medical devices, implants and wound dressings | |
| CN114129762B (en) | Electrostatic spinning nanofiber membrane loaded with self-assembled traditional Chinese medicine ingredient vesicles and preparation method and application thereof | |
| CN113876995B (en) | Nanofiber membrane for skin wound and preparation method thereof | |
| CN114015078A (en) | PH self-adjusting dual-response hydrogel and synthesis method and application thereof | |
| CN108524942A (en) | A kind of pH responsive type medicine-carried nano particles and preparation method thereof based on ganoderma lucidum polysaccharide-histidine conjugate | |
| CN112426537A (en) | Polypeptide nano micelle and preparation method and application thereof | |
| CN111803696A (en) | Preparation method of patchouli oil nano composite membrane for skin wound repair | |
| CN116059429B (en) | Dressing for healing chronic wounds of diabetes and preparation method thereof | |
| CN116942892B (en) | Hydrogel dressing for treating diabetes wound surface and preparation method thereof | |
| CN116473907A (en) | Microneedle carrying antioxidant drug particles and preparation method thereof | |
| CN117018273A (en) | NMN and Mg-based 2+ Synergistic multifunctional hydrogel and preparation method and application thereof | |
| CN116850335A (en) | Composite film for skin wound dressing and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |